Loading publications…
The last 5 uploaded publications
67 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBANALYSIS OF SHARP TRIAL BASED ON BARCELONA CLINIC LIVER CANCER (BCLC) STAGE
Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Ming Shan, Giuseppe Lentini, Andrea Nadel, D. Voliotis, Josep M. Llovet (2009). 67 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBANALYSIS OF SHARP TRIAL BASED ON BARCELONA CLINIC LIVER CANCER (BCLC) STAGE. Journal of Hepatology, 50, pp. S28-S29, DOI: 10.1016/s0168-8278(09)60069-6.
Article145 days agoSorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean Frédéric Blanc, André Cosme de Oliveira, Armando Santoro, Jean‐Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F. Greten, Peter R. Galle, Jean François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, M. Moscovici, D. Voliotis, Jordi Bruix (2008). Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 359(4), pp. 378-390, DOI: 10.1056/nejmoa0708857.
Article145 days agoEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle, Alejandro Forner, Josep M. Llovet, Vincenzo Mazzaferro, Fabio Piscaglia, Jean‐Luc Raoul, Peter Schirmacher, Valérie Vilgrain (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69(1), pp. 182-236, DOI: 10.1016/j.jhep.2018.03.019.
Article145 days agoEfficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet (2012). Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology, 57(4), pp. 821-829, DOI: 10.1016/j.jhep.2012.06.014.
Article145 days agoBrivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon‐Koo Kang, Éric Assenat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Deng‐Yn Lin, Jordi Bruix, Ronnie T.P. Poon, Morris Sherman, Jean–Frédéric Blanc, Richard S. Finn, Won Young Tak, Yee Chao, Rana Ezzeddine, David Liu, Ian Walters, Joong‐Won Park (2013). Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 31(28), pp. 3509-3516, DOI: 10.1200/jco.2012.47.3009.
Article145 days ago